Evenity (romosozumab) is not a bisphosphonate. It belongs to a completely different drug class: it’s a humanized monoclonal antibody that works by blocking a protein called sclerostin. While bisphosphonates slow down bone loss, Evenity actively builds new bone, making it fundamentally different in both its chemistry and how it works in your body.
How Evenity Works vs. Bisphosphonates
The confusion is understandable because both Evenity and bisphosphonates treat osteoporosis. But they attack the problem from opposite directions.
Bisphosphonates are antiresorptive drugs. They bind tightly to bone surfaces and get absorbed by the cells responsible for breaking down bone (osteoclasts), essentially slowing or stopping bone loss. Common bisphosphonates include alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), and zoledronic acid (Reclast). These drugs preserve the bone you already have, but they don’t stimulate your body to build much new bone.
Evenity is an anabolic agent, meaning it triggers new bone formation. Your body naturally produces a protein called sclerostin, which acts like a brake on bone-building cells (osteoblasts). Evenity blocks sclerostin, releasing that brake so osteoblasts can ramp up production of new bone tissue. It also reduces bone breakdown to a lesser degree, giving it a dual effect that no bisphosphonate can match. It’s the first medication to both increase bone formation and reduce bone resorption at the same time.
Fracture Reduction Compared to a Bisphosphonate
The ARCH trial directly compared Evenity against alendronate, one of the most widely prescribed bisphosphonates. After 12 months, patients on Evenity had a 37% lower risk of new vertebral fractures and a 28% lower risk of clinical fractures compared to those on alendronate. Hip fracture risk dropped by 36%. In the FRAME trial, which compared Evenity to placebo, patients saw a 73% reduction in new vertebral fractures and a 36% reduction in clinical fractures after one year.
These numbers reflect the advantage of actively building bone rather than just preventing further loss, particularly in patients at high risk for fractures.
How Evenity Is Given
Evenity is a monthly injection given under the skin in your abdomen, thigh, or upper arm. Each visit actually requires two separate injections (two prefilled syringes of 105 mg each) to deliver the full 210 mg dose. Treatment is limited to 12 monthly doses, so you’ll receive it for exactly one year.
This is quite different from bisphosphonates, which come in various forms. Some are daily or weekly pills, others are monthly pills, and zoledronic acid is an intravenous infusion given once a year. Bisphosphonates can be taken for years, though doctors often recommend periodic breaks.
Why Evenity Is Often Followed by a Bisphosphonate
Here’s where the two drug classes intersect in a way that catches many patients off guard: after your 12 months of Evenity, you’ll almost certainly be switched to a bisphosphonate or another antiresorptive medication. Without follow-on therapy, the bone density gains from Evenity typically drift back toward pre-treatment levels. A bisphosphonate like alendronate or zoledronic acid locks in those gains by preventing the newly built bone from being broken down.
Think of it as a two-phase strategy. Evenity does the heavy construction work, rapidly adding bone mass and strength. The bisphosphonate that follows acts as the maintenance crew, keeping that new bone intact over the long term. Some patients may even repeat a second 12-month course of Evenity after spending a year or more on antiresorptive therapy, though this approach is less commonly studied.
Who Evenity Is Designed For
Evenity is approved for postmenopausal women with osteoporosis who are at high risk of fracture. Because of its bone-building power, it tends to be reserved for patients with very low bone density, a history of fractures, or those who haven’t responded well to other treatments. It’s not typically a first-line option for mild bone loss.
Your calcium levels need to be normal before starting treatment, and your provider will likely check them beforehand. Evenity also carries a boxed warning related to cardiovascular risk, so it’s generally not recommended for people who have had a heart attack or stroke within the past year. This is another significant difference from bisphosphonates, which don’t carry the same cardiovascular concern.
Quick Comparison at a Glance
- Drug class: Evenity is a monoclonal antibody (sclerostin inhibitor). Bisphosphonates are a separate chemical class of antiresorptive drugs.
- Primary action: Evenity builds new bone. Bisphosphonates prevent bone breakdown.
- Duration: Evenity is limited to 12 months. Bisphosphonates can be used for years.
- Administration: Evenity is two subcutaneous injections monthly. Bisphosphonates are pills (daily, weekly, or monthly) or annual IV infusions.
- Sequencing: Evenity is typically given first, then followed by a bisphosphonate to maintain results.